{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:47:01Z","timestamp":1791845221899,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10072-026-09306-8","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T01:16:24Z","timestamp":1786756584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cEfficacy, safety and certainty of evidence for selective D1\/D5 dopamine receptor partial agonists in Parkinson\u2019s disease: a systematic review, meta-analysis and GRADE assessment\u201d"],"prefix":"10.1007","volume":"47","author":[{"given":"Ahmad Akhtar","family":"Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9455-298X","authenticated-orcid":false,"given":"Umamah","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabiha","family":"Naz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhtar","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"issue":"8","key":"9306_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A (2017) Epidemiology of Parkinson\u2019s disease. J Neural Transm (Vienna) 124(8):901\u2013905. https:\/\/doi.org\/10.1007\/s00702-017-1686-y","journal-title":"J Neural Transm (Vienna)"},{"key":"9306_CR2","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J et al (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"issue":"11","key":"9306_CR3","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators (2018) Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):939\u2013953. https:\/\/doi.org\/10.1016\/S1474-4422(18)30295-3","journal-title":"Lancet Neurol"},{"issue":"5","key":"9306_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson\u2019s disease in the most populous nations, 2005 through 2030. Neurology 68(5):384\u2013386. https:\/\/doi.org\/10.1212\/01.wnl.0000247740.47667.03","journal-title":"Neurology"},{"issue":"20","key":"9306_CR5","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ et al (2021) Dopaminergic therapy for motor symptoms in early Parkinson\u2019s disease: practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology 97(20):942\u2013957. https:\/\/doi.org\/10.1212\/WNL.0000000000012868","journal-title":"Neurology"},{"key":"9306_CR6","unstructured":"National Institute for Health and Care Excellence (2017) Parkinson\u2019s disease in adults. NICE guideline [NG71]. London: NICE. Available from: https:\/\/www.nice.org.uk\/guidance\/ng71"},{"issue":"11","key":"9306_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2165\/00002018-200124110-00007","volume":"24","author":"M Etminan","year":"2001","unstructured":"Etminan M, Samii A, Takkouche B, Rochon PA (2001) Increased risk of somnolence with the new dopamine agonists in patients with Parkinson\u2019s disease: a meta-analysis of randomised controlled trials. Drug Saf 24(11):863\u2013868. https:\/\/doi.org\/10.2165\/00002018-200124110-00007","journal-title":"Drug Saf"},{"issue":"4","key":"9306_CR8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s10072-023-07254-1","volume":"45","author":"LG Soileau","year":"2024","unstructured":"Soileau LG, Talbot NC, Storey NR, Spillers NJ, D\u2019Antoni JV, Carr PC et al (2024) Impulse control disorders in Parkinson\u2019s disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis. Neurol Sci 45(4):1399\u20131408. https:\/\/doi.org\/10.1007\/s10072-023-07254-1","journal-title":"Neurol Sci"},{"key":"9306_CR9","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.prdoa.2023.100212","volume":"9","author":"SH Isaacson","year":"2023","unstructured":"Isaacson SH, Hauser RA, Pahwa R, Gray DL, Duvvuri S (2023) Dopamine agonists in Parkinson\u2019s disease: impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. Clin Park Relat Disord 9:100212. https:\/\/doi.org\/10.1016\/j.prdoa.2023.100212","journal-title":"Clin Park Relat Disord"},{"key":"9306_CR10","doi-asserted-by":"publisher","first-page":"175628642091129","DOI":"10.1177\/1756286420911296","volume":"13","author":"R Riesenberg","year":"2020","unstructured":"Riesenberg R, Werth J, Zhang Y, Duvvuri S, Gray DL (2020) PF-06649751 efficacy and safety in early Parkinson\u2019s disease: a randomized, placebo-controlled trial. Ther Adv Neurol Disord 13:1756286420911296. https:\/\/doi.org\/10.1177\/1756286420911296","journal-title":"Ther Adv Neurol Disord"},{"key":"9306_CR11","doi-asserted-by":"publisher","unstructured":"Pahwa R, Moro E, Espay AJ, Evans A, Saint-Hilaire MH, Torres-Russotto D et al (2026) Fixed-dose tavapadon for early Parkinson\u2019s disease: a randomized clinical trial. JAMA Neurol 20:e260590. https:\/\/doi.org\/10.1001\/jamaneurol.2026.0590","DOI":"10.1001\/jamaneurol.2026.0590"},{"key":"9306_CR12","doi-asserted-by":"publisher","unstructured":"Fernandez HH, Isaacson SH, Hauser RA, Agarwal P, Ondo W, Park A et al (2026) Tavapadon as adjunctive treatment for Parkinson\u2019s disease: the TEMPO-3 randomized clinical trial. JAMA Neurol 20:e260577. https:\/\/doi.org\/10.1001\/jamaneurol.2026.0577","DOI":"10.1001\/jamaneurol.2026.0577"},{"key":"9306_CR13","unstructured":"AbbVie (2025) AbbVie submits new drug application to US FDA for tavapadon for the treatment of Parkinson\u2019s disease. North Chicago (IL): AbbVie. Available from: https:\/\/news.abbvie.com\/2025-09-26-AbbVie-Submits-New-Drug-Application-to-U-S-FDA-for-Tavapadon-for-the-Treatment-of-Parkinsons-Disease"},{"key":"9306_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"12","key":"9306_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mds.20248","volume":"19","author":"RA Hauser","year":"2004","unstructured":"Hauser RA, Deckers F, Lehert P (2004) Parkinson\u2019s disease home diary: further validation and implications for clinical trials. Mov Disord 19(12):1409\u20131413. https:\/\/doi.org\/10.1002\/mds.20248","journal-title":"Mov Disord"},{"key":"9306_CR16","unstructured":"Pfizer Inc (2026) A 15-week, phase 2, double-blind, randomized, placebo-controlled, dose-ranging study to investigate the efficacy, safety and tolerability of PF-06649751 in subjects with motor fluctuations due to Parkinson\u2019s disease (protocol B7601003) [unpublished registry results]. ClinicalTrials.gov identifier: NCT02687542. Terminated 25 September 2017. Accessed May Available from: https:\/\/clinicaltrials.gov\/study\/NCT02687542"},{"key":"9306_CR17","unstructured":"Higgins JP, Li T, Deeks JJ (2024) Chapter 6: choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane"},{"key":"9306_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"issue":"7650","key":"9306_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"4","key":"9306_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u2013406","journal-title":"J Clin Epidemiol"},{"key":"9306_CR21","unstructured":"Sch\u00fcnemann H, Br\u017eo\u017ea T, Oxman A (eds) (2013) GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group. Available from: https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html"},{"key":"9306_CR22","unstructured":"AbbVie, Inc (2026) A phase 3, double-blind, randomized, placebo-controlled, parallel-group, flexible-dose, 27-week trial to evaluate the efficacy, safety, and tolerability of tavapadon in early Parkinson\u2019s disease (TEMPO-2) [unpublished registry results]. ClinicalTrials.gov identifier: NCT04223193. Results first posted 21 November 2025. Accessed March Available from: https:\/\/clinicaltrials.gov\/study\/NCT04223193"},{"issue":"3","key":"9306_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3102\/10769986030003261","volume":"30","author":"W Viechtbauer","year":"2005","unstructured":"Viechtbauer W (2005) Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. J Educ Behav Stat 30(3):261\u2013293. https:\/\/doi.org\/10.3102\/10769986030003261","journal-title":"J Educ Behav Stat"},{"key":"9306_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol 14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25","journal-title":"BMC Med Res Methodol"},{"key":"9306_CR25","unstructured":"Deeks JJ, Higgins JP, Altman DG, McKenzie JE, Veroniki AA (2024) Chapter 10: analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (eds). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane"},{"issue":"24","key":"9306_CR26","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","volume":"20","author":"J Hartung","year":"2001","unstructured":"Hartung J, Knapp G (2001) A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med 20(24):3875\u20133889. https:\/\/doi.org\/10.1002\/sim.1009","journal-title":"Stat Med"},{"issue":"7414","key":"9306_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"9306_CR28","unstructured":"Higgins JP, Eldridge S, Li T et al (2024) Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane"},{"issue":"2","key":"9306_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JPD-181302","volume":"8","author":"S Papapetropoulos","year":"2018","unstructured":"Papapetropoulos S, Liu W, Duvvuri S et al (2018) Evaluation of D1\/D5 partial agonist PF-06412562 in Parkinson\u2019s disease following oral administration. J Parkinsons Dis 8(2):293\u2013302. https:\/\/doi.org\/10.3233\/JPD-181302","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"9306_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/WNF.0000000000000388","volume":"43","author":"X Huang","year":"2020","unstructured":"Huang X, Bhatt MB, Cheshire WP et al (2020) The D1\/D5 dopamine partial agonist PF-06412562 in advanced-stage Parkinson\u2019s disease: a feasibility study. Clin Neuropharmacol 43(3):67\u201372. https:\/\/doi.org\/10.1097\/WNF.0000000000000388","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"9306_CR31","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/wnl.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17(5):427\u2013442. https:\/\/doi.org\/10.1212\/wnl.17.5.427","journal-title":"Neurology"},{"issue":"8","key":"9306_CR32","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/mds.20914","volume":"21","author":"A Schrag","year":"2006","unstructured":"Schrag A, Sampaio C, Counsell N, Poewe W (2006) Minimal clinically important change on the unified Parkinson\u2019s disease rating scale. Mov Disord 21(8):1200\u20131207. https:\/\/doi.org\/10.1002\/mds.20914","journal-title":"Mov Disord"},{"issue":"1","key":"9306_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archneurol.2009.295","volume":"67","author":"LM Shulman","year":"2010","unstructured":"Shulman LM, Gruber-Baldini AL, Anderson KE et al (2010) The clinically important difference on the Unified Parkinson\u2019s Disease Rating Scale. Arch Neurol 67(1):64\u201370. https:\/\/doi.org\/10.1001\/archneurol.2009.295","journal-title":"Arch Neurol"},{"issue":"5","key":"9306_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.tins.2007.03.008","volume":"30","author":"DJ Surmeier","year":"2007","unstructured":"Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30(5):228\u2013235. https:\/\/doi.org\/10.1016\/j.tins.2007.03.008","journal-title":"Trends Neurosci"},{"key":"9306_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1054-3589(06)54004-9","volume":"54","author":"RB Mailman","year":"2007","unstructured":"Mailman RB (2007) D1 dopamine receptors in neuropsychiatric disorders: never as simple as expected. Adv Pharmacol 54:77\u2013109. https:\/\/doi.org\/10.1016\/S1054-3589(06)54004-9","journal-title":"Adv Pharmacol"},{"key":"9306_CR36","doi-asserted-by":"publisher","unstructured":"Stowe RL, Ives NJ, Clarke C et al (2008) Dopamine agonist therapy in early Parkinson\u2019s disease. Cochrane Database Syst Rev 2CD006564. https:\/\/doi.org\/10.1002\/14651858.CD006564.pub2","DOI":"10.1002\/14651858.CD006564.pub2"},{"issue":"8","key":"9306_CR37","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY et al (2018) International Parkinson and Movement Disorder Society evidence-based medicine review: update and new evidence 2018. Mov Disord 33(8):1248\u20131266. https:\/\/doi.org\/10.1002\/mds.27372","journal-title":"Mov Disord"},{"issue":"15","key":"9306_CR38","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"issue":"2","key":"9306_CR39","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Costa J et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomized, double-blind, controlled trial (BIPARK-I). Lancet Neurol 15(2):154\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(15)00336-1","journal-title":"Lancet Neurol"},{"issue":"2","key":"9306_CR40","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1001\/jamaneurol.2016.4602","volume":"74","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Fox SH, Hauser RA et al (2017) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson\u2019s disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):216\u2013224. https:\/\/doi.org\/10.1001\/jamaneurol.2016.4602","journal-title":"JAMA Neurol"},{"issue":"10","key":"9306_CR41","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archneur.61.10.1563","volume":"61","author":"CW Olanow","year":"2004","unstructured":"Olanow CW, Kieburtz K, Stern M et al (2004) Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson\u2019s disease. Arch Neurol 61(10):1563\u20131568. https:\/\/doi.org\/10.1001\/archneur.61.10.1563","journal-title":"Arch Neurol"},{"issue":"Suppl 3","key":"9306_CR42","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/S1353-8020(09)70771-9","volume":"15","author":"MA Stacy","year":"2009","unstructured":"Stacy MA (2009) Natural history and clinical features of Parkinson\u2019s disease with motor fluctuations. Parkinsonism Relat Disord 15(Suppl 3):S4\u2013S9. https:\/\/doi.org\/10.1016\/S1353-8020(09)70771-9","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"9306_CR43","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0014-2999(91)90502-k","volume":"199","author":"JR Taylor","year":"1991","unstructured":"Taylor JR, Lawrence MS, Redmond DE Jr et al (1991) Dihydrexidine, a full dopamine D1 receptor agonist, reduces MPTP-induced Parkinsonism in monkeys. Eur J Pharmacol 199(3):389\u2013391. https:\/\/doi.org\/10.1016\/0014-2999(91)90502-k","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"9306_CR44","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/1531-8249(199906)45:6<736::aid-ana8>3.0.co;2-k","volume":"45","author":"O Rascol","year":"1999","unstructured":"Rascol O, Blin O, Thalamas C et al (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson\u2019s disease. Ann Neurol 45(6):736\u2013741. https:\/\/doi.org\/10.1002\/1531-8249(199906)45:6%3C736::aid-ana8%3E3.0.co;2-k","journal-title":"Ann Neurol"},{"issue":"5","key":"9306_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","volume":"16","author":"RB Mailman","year":"2010","unstructured":"Mailman RB, Murthy V (2010) Third-generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 16(5):488\u2013501. https:\/\/doi.org\/10.2174\/138161210790361461","journal-title":"Curr Pharm Des"},{"issue":"5","key":"9306_CR46","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson\u2019s disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"issue":"3","key":"9306_CR47","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1212\/WNL.0000000000005816","volume":"91","author":"JC Corvol","year":"2018","unstructured":"Corvol JC, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson\u2019s disease. Neurology 91(3):e189\u2013e201. https:\/\/doi.org\/10.1212\/WNL.0000000000005816","journal-title":"Neurology"},{"issue":"9","key":"9306_CR48","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1212\/wnl.52.9.1908","volume":"52","author":"S Frucht","year":"1999","unstructured":"Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52(9):1908\u20131910. https:\/\/doi.org\/10.1212\/wnl.52.9.1908","journal-title":"Neurology"},{"issue":"6","key":"9306_CR49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/mds.10417","volume":"18","author":"S Paus","year":"2003","unstructured":"Paus S, Brecht HM, Koster J et al (2003) Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson\u2019s disease. Mov Disord 18(6):659\u2013667. https:\/\/doi.org\/10.1002\/mds.10417","journal-title":"Mov Disord"},{"issue":"16","key":"9306_CR50","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson\u2019s disease: a review. JAMA 311(16):1670\u20131683. https:\/\/doi.org\/10.1001\/jama.2014.3654","journal-title":"JAMA"},{"issue":"9","key":"9306_CR51","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrn2471","volume":"9","author":"P Jenner","year":"2008","unstructured":"Jenner P (2008) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9(9):665\u2013677. https:\/\/doi.org\/10.1038\/nrn2471","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"9306_CR52","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tins.2007.03.005","volume":"30","author":"MA Cenci","year":"2007","unstructured":"Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30(5):236\u2013243. https:\/\/doi.org\/10.1016\/j.tins.2007.03.005","journal-title":"Trends Neurosci"},{"issue":"12","key":"9306_CR53","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol O, Fabbri M, Poewe W (2021) Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol 20(12):1048\u20131056. https:\/\/doi.org\/10.1016\/S1474-4422(21)00249-0","journal-title":"Lancet Neurol"},{"key":"9306_CR54","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM et al (2017) Parkinson\u2019s disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"issue":"36","key":"9306_CR55","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.181504","volume":"191","author":"D Grimes","year":"2019","unstructured":"Grimes D, Fitzpatrick M, Gordon J et al (2019) Canadian guideline for Parkinson\u2019s disease. CMAJ 191(36):E989\u2013E1004. https:\/\/doi.org\/10.1503\/cmaj.181504","journal-title":"CMAJ"},{"issue":"10291","key":"9306_CR56","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"key":"9306_CR57","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41531-020-0117-1","volume":"6","author":"W Yang","year":"2020","unstructured":"Yang W, Hamilton JL, Kopil C, Beck JC, Tanner CM, Dorsey ER et al (2020) Current and projected future economic burden of Parkinson\u2019s disease in the U.S. npj Parkinsons Dis 6:15. https:\/\/doi.org\/10.1038\/s41531-020-0117-1","journal-title":"npj Parkinsons Dis"},{"issue":"12","key":"9306_CR58","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s10072-018-3564-4","volume":"39","author":"A Antonini","year":"2018","unstructured":"Antonini A, Gentile G, Giglio M et al (2018) Patient- and caregiver-related burden in advanced Parkinson\u2019s disease. Neurol Sci 39(12):2131\u20132138. https:\/\/doi.org\/10.1007\/s10072-018-3564-4","journal-title":"Neurol Sci"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09306-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:02:11Z","timestamp":1791842531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09306-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["9306"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09306-8","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]},"assertion":[{"value":"16 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since this work is a systematic evaluation of already published research, informed consent and institutional review board approval were not necessary, and no additional human or animal participants were enlisted.","order":1,"name":"Ethics","label":"Ethical conduct of research","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"none of the authors have any conflicting interests to declare.","order":2,"name":"Ethics","label":"Conflicting interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"708"}}